中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (2): 156-160.doi: 10.19401/j.cnki.1007-3639.2018.02.013

• 综述 • 上一篇    

葡萄糖调节蛋白78与肿瘤耐药和靶向治疗进展

郑以孜 综述,邵志敏 审校   

  1. 复旦大学附属肿瘤医院乳腺外科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2018-02-28 发布日期:2018-03-08
  • 通信作者: 邵志敏 E-mail:zhi_ming_shao@163.com

Research progress on glucose-regulated protein 78 in drug resistance and targeted therapy for cancer

ZHENG Yizi, SHAO Zhimin   

  1. Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2018-02-28 Online:2018-03-08
  • Contact: SHAO Zhimin E-mail: zhi_ming_shao@163. com

摘要: 葡萄糖调节蛋白78(glucose-regulated protein 78,GRP78)在肿瘤耐药发生中具有重要作用,针对GRP78的靶向治疗已成为抗癌治疗的研究热点。该研究简要介绍了葡萄糖调节蛋白78,总结其与化疗、内分泌治疗、靶向治疗等治疗耐药的关系以及耐药机制,同时总结了GRP78靶向治疗方面的研究进展。

关键词: 葡萄糖调节蛋白78, 肿瘤, 耐药, 靶向治疗

Abstract: Glucose-regulated protein 78 (GRP78) plays an important role in the development of drug resistance in cancer, and GRP78 targeted therapy has become a hotspot of cancer research. In this article, we briefly introduce GRP78, review the research progress on the roles of GRP78 in drug resistance to cancer therapies, including chemotherapy, endocrine therapy and targeted therapy, and the mechanisms of resistance. The progress on GRP78 targeted therapy for cancer is also summarized.

Key words: Glucose-regulated protein 78, Cancer, Drug resistance, Targeted therapy